When hemolysis
remains ongoing

ARE THE
SYMPTOMS OF
PNH HOLDING YOUR
PATIENTS BACK?

Replay
Ongoing burden of hemolysis
C5 inhibition has improved patient survival by addressing IVH, yet many patients with PNH continue to experience symptoms of ongoing hemolysis and persistently low
Hb1-4
According to two retrospective
studies (N=141; N=58) of patients
treated with C5 inhibitors5,6*†:
had persistently
LOW Hb
(<12g/dL), a key indicator of ongoing hemolysis
BELOW NORMAL Hb LEVELS, INDICATIVE OF
ONGOING HEMOLYSIS, SHOW A STRONG
CORRELATION TO QoL PARAMETERS (r=0.76).7
72% of patients had anemia (<12 g/dL) a key indicator of ongoing hemolysis
required ≥1
RBC
TRANSFUSION
in a 12-month period, with 16% requiring ≥3
36% needed ≥ RBC transfusion in a 12-month period, with 16% requiring ≥3

EVH=extravascular hemolysis; Hb=hemoglobin; LDH=lactate dehydrogenase; PNH=paroxysmal nocturnal hemoglobinuria; QoL=quality of life; RBC=red blood cell.
*A retrospective analysis of eculizumab-treated patients with PNH treated in the Leeds Center of the UK PNH National Service was conducted to determine if laboratory parameters apart from LDH are stronger indicators of EVH. The poster was presented at the 2017 ASH Annual Meeting (McKinley et al) and the abstract published in Blood 2017.6
†A cross-sectional survey was administered to adult patients ≥18 years of age being treated with either eculizumab or ravulizumab in the US with a self-reported diagnosis of PNH. Patients were recruited through a patient advocacy group in July 2020. The survey is ongoing and the results are preliminary. This abstract was presented at the 2020 ASH Annual Meeting (Dingli et al) and published in Blood 2020.5

C5 inhibition has improved patient
survival by addressing IVH, yet many
patients with PNH continue to experience
symptoms of ongoing hemolysis and
persistently low Hb1-4
Uncover the ongoing burden
HEMOLYSIS REMAINS ONGOING IN
MANY TREATED PATIENTS WITH PNH1,4,8,9
According to a retrospective analysis (N=93),
up to 89% of patients treated with C5
inhibition showed varying signs of
ongoing hemolysis8‡
Explore complement
pathway inhibition Watch for more information
on hemolysis

‡An international, retrospective analysis of 93 patients with PNH was conducted to classify hematologic response to eculizumab based on hemoglobin levels and residual hemolysis (Debureaux ASH Abstract 2019). The calculation of hematologic response is from the last 6 months, inclusive of major, good, partial, minor, and non-responders.8

According to a retrospective analysis (N=141),
UP TO 100% OF TREATED PATIENTS
SHOWED SOME evidence of
C3-loading
of PNH RBCs,
suggesting the incidence of EVH may
be higher than previously thought6§
Start identifying signs of EVH

§A retrospective analysis of eculizumab-treated patients with PNH treated in the Leeds Center of the UK PNH National Service was conducted to determine if laboratory parameters apart from LDH are stronger indicators of EVH. The poster was presented at the 2017 ASH Annual Meeting (McKinley et al) and the abstract published in Blood 2017.6

Learn more about PNH
Discover helpful
resources Visit our patient
website
Back to Top

*A retrospective analysis of eculizumab-treated patients with PNH treated in the Leeds Center of the UK PNH National Service was conducted to determine if laboratory parameters apart from LDH are stronger indicators of EVH. The poster was presented at the 2017 ASH Annual Meeting (McKinley et al) and the abstract published in Blood 2017.6
†A cross-sectional survey was administered to adult patients ≥18 years of age being treated with either eculizumab or ravulizumab in the US with a self-reported diagnosis of PNH. Patients were recruited through a patient advocacy group in July 2020. The survey is ongoing and the results are preliminary. This abstract was presented at the 2020 ASH Annual Meeting (Dingli et al) and published in Blood 2020.5
‡An international, retrospective analysis of 93 patients with PNH was conducted to classify hematologic response to eculizumab based on hemoglobin levels and residual hemolysis (Debureaux ASH Abstract 2019). The calculation of hematologic response is from the last 6 months, inclusive of major, good, partial, minor, and non-responders.8
§A retrospective analysis of eculizumab-treated patients with PNH treated in the Leeds Center of the UK PNH National Service was conducted to determine if laboratory parameters apart from LDH are stronger indicators of EVH. The poster was presented at the 2017 ASH Annual Meeting (McKinley et al) and the abstract published in Blood 2017.6

EVH=extravascular hemolysis; Hb=hemoglobin; IVH=intravascular hemolysis; LDH=lactate dehydrogenase; PNH=paroxysmal nocturnal hemoglobinuria; QoL=quality of life; RBC=red blood cell.

References: 1. Hill A, et al. Nat Rev Dis Primers. 2017;3:17028. 2. Lee JW, et al. Am J Hematol. 2019;94:S1-S2. 3. Loschi M, et al. Am J Hematol. 2016;91(4):366-370. 4. Risitano AM, et al. Blood. 2009;113(17):4094-4100. 5. Dingli D, et al. Blood. 2020;136(suppl 1):2. 6. McKinley CE, et al. Blood. 2017;130(suppl 1):3471. 7. Ueda Y, et al. Int J Hematol. 2018;107(6):656-665. 8. Debureaux PE, et al. Abstract presented at: 61st American Society of Hematology Annual Meeting; December 7-10, 2019: San Diego, CA. 9. Risitano AM, et al. Front Immunol. 2019;10:1157.